S2L.F BAUSCH + LOMB CORP.

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
18.90 EUR
Close of Nov 12, 2026
12.50 19.10
Market cap
EUR 6.76B
P/E
-
P/B
1.18x
ROE
-1.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is S2L.F undervalued?

Graham number

The Graham number of BAUSCH + LOMB CORP. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BAUSCH + LOMB CORP. fundamental analysis

No fundamental analysis for BAUSCH + LOMB CORP. yet.

BAUSCH + LOMB CORP. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BAUSCH + LOMB CORP.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are in…

Full company profile